|
| | (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Basic information |
| Product Name: | (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID | | Synonyms: | (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID;(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID: HYDROCHLORIDE;ACE/TA-6366;Novarok;SH-6366;Imidaprilhydrochloride;4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, monohydrochloride, (4S)-;4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, monohydrochloride, [4S-[3[R*(R*)],4R*]]- | | CAS: | 89396-94-1 | | MF: | C20H27N3O6 | | MW: | 405.44488 | | EINECS: | 685-551-0 | | Product Categories: | Inhibitors | | Mol File: | 89396-94-1.mol | ![(S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Structure](CAS/GIF/89396-94-1.gif) |
| | (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Chemical Properties |
| Melting point | 214-216℃ | | alpha | D20 -64.1° (c = 0.5 in ethanol) | | storage temp. | -20°C | | solubility | H2O: ≥5mg/mL | | form | powder | | color | white to tan | | optical activity | [α]/D -50 to -70° in ethanol (c=0.5) | | Merck | 14,4911 |
| WGK Germany | 3 | | RTECS | NI8927400 | | HS Code | 2933.29.4300 |
| | (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Usage And Synthesis |
| Uses | antibiotic | | Uses | Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive. | | Uses | Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method. | | Definition | ChEBI: Imidapril hydrochloride is a dipeptide. | | General Description | Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1. | | Biochem/physiol Actions | Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive. | | Clinical Use | Angiotensin-converting enzyme inhibitor:
Hypertension | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.
Bee venom extract: possible severe anaphylactoid
reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and
nephrotoxicity.
Cytotoxics: increased risk of angioedema with
everolimus.
Diuretics: enhanced hypotensive effect;
hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.
Gold: flushing and hypotension with sodium
aurothiomalate.
Lithium: reduced excretion, possibility of enhanced
lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and
nephrotoxicity. | | Metabolism | Imidapril is a prodrug, and is metabolised in the liver
to the diacid imidaprilat, its active metabolite. The
bioavailability of imidaprilat is about 42% after oral doses
of imidapril.
About 40% of an oral dose is excreted in the urine, the
rest in the faeces. |
| | (S)-3-[(S)-2-((S)-1-ETHOXYCARBONYL-3-PHENYL-PROPYLAMINO)-PROPIONYL]-1-METHYL-2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID Preparation Products And Raw materials |
|
